June 24, 2018 1:29 PM ET


Company Overview of Hoffmann-La Roche Inc.

Company Overview

Hoffmann-La Roche Inc. researches, develops, and manufactures medicines, diagnostics, and vitamins. It offers drugs and in-vitro diagnostics for cancer and transplantation; and therapeutic products for cancer, neuroscience, infectious diseases, immunology, cardiovascular, and metabolism diseases. Hoffmann-La Roche Inc. was formerly known as Roche Chemical Works Inc. and changed its name to Hoffmann-La Roche Inc. in 1929. The company was founded in 1905 and is headquartered in Nutley, New Jersey. Hoffmann-La Roche Inc. operates as a subsidiary of Roche Holding AG.

340 Kingsland Street

Nutley, NJ 07110

United States

Founded in 1905





Key Executives for Hoffmann-La Roche Inc.

Hoffmann-La Roche Inc. does not have any Key Executives recorded.

Hoffmann-La Roche Inc. Key Developments

MacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific Molecule

MacroGenics, Inc. announced that it had entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to jointly discover and develop novel bispecific molecules to undisclosed targets. During the research term, both companies will leverage their respective platforms, including MacroGenics’ DART® platform and Roche’s CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate. Under the terms of the agreement, Roche will pay MacroGenics an upfront payment of $10 million. MacroGenics will also be eligible to receive up to $370 million in potential milestone payments and royalties on future sales.

FDA Expands Approved Use of Hoffman La Roche, Inc.'s Actemra to Treat Giant Cell Arteritis

Hoffman La Roche Inc. has announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis. The efficacy and safety of subcutaneous (injected under the skin) Actemra for giant cell arteritis were established in a double-blind, placebo-controlled study with 251 patients with giant cell arteritis. The primary efficacy endpoint was the proportion of patients achieving sustained remission from Week 12 through Week 52. Sustained remission was defined as the absence of symptoms of giant cell arteritis, normalization of inflammatory laboratory tests, and tapering the use of prednisone (a steroid drug). A greater proportion of patients receiving subcutaneous Actemra with standardized prednisone regimens achieved sustained remission from Week 12 through Week 52 as compared to patients receiving placebo with standardized prednisone regimens. The cumulative prednisone dose was lower in treated patients with Actemra relative to placebo. The overall safety profile observed in the Actemra treatment groups was generally consistent with the known safety profile of Actemra.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hoffmann-La Roche Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.